CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
36.99
-1.05 (-2.76%)
At close: Mar 28, 2025, 4:00 PM
35.44
-1.55 (-4.19%)
Pre-market: Mar 31, 2025, 8:53 AM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 74.35, with a low estimate of 32 and a high estimate of 120. The average target predicts an increase of 101.00% from the current stock price of 36.99.
Analyst Consensus: Buy
* Price targets were last updated on Feb 18, 2025.
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 7 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 9 | 9 | 9 | 9 | 9 | 8 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 18 | 19 | 21 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 19, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $89 → $82 | Strong Buy | Maintains | $89 → $82 | +121.68% | Feb 18, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $30 → $32 | Sell | Maintains | $30 → $32 | -13.49% | Feb 14, 2025 |
| Evercore ISI Group | Evercore ISI Group | Hold → Buy Upgrades $60 → $99 | Hold → Buy | Upgrades | $60 → $99 | +167.64% | Feb 14, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $66 → $57 | Hold | Maintains | $66 → $57 | +54.10% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
55.88M
from 37.31M
Increased by 49.76%
Revenue Next Year
199.65M
from 55.88M
Increased by 257.28%
EPS This Year
-4.98
from -4.34
EPS Next Year
-4.14
from -4.98
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 164.9M | 1.6B | 2.4B | ||
| Avg | 55.9M | 199.7M | 486.2M | ||
| Low | n/a | n/a | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 341.8% | 2,680.9% | 1,092.1% | ||
| Avg | 49.8% | 257.3% | 143.5% | ||
| Low | - | - | -55.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.06 | 4.15 | 5.79 | ||
| Avg | -4.98 | -4.14 | -1.97 | ||
| Low | -6.80 | -7.54 | -6.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.